Advancing Hepatitis C Elimination through Opt-Out Universal Screening and Treatment in Carceral Settings, United States.
Emerg Infect Dis
; 30(13): S80-S87, 2024 04.
Article
em En
| MEDLINE
| ID: mdl-38561831
ABSTRACT
Incarcerated persons are infected with hepatitis C virus (HCV) at rates ≈10 times higher than that of the general population in the United States. To achieve national hepatitis C elimination goals, the diagnosis and treatment of hepatitis C in incarcerated persons must be prioritized. In 2022, the Centers for Disease Control and Prevention recommended that all persons receive opt-out HCV screening upon entry into a carceral setting. We review recommendations, treatments, and policy strategies used to promote HCV opt-out universal HCV screening and treatment in incarcerated populations in the United States. Treatment of hepatitis C in carceral settings has increased but varies by jurisdiction and is not sufficient to achieve HCV elimination. Strengthening universal HCV screening and treatment of HCV-infected incarcerated persons is necessary for HCV elimination nationwide.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hepatite C
/
Hepacivirus
Limite:
Humans
País como assunto:
America do norte
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article